Observational studyCardiology journal2025
Validation of the COAPT risk score in Polish patients undergoing transcatheter edge-to-edge repair of severe, functional mitral regurgitation: a multicenter, observational study.
Observational study in Cardiology journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COAPT risk score, developed based on the COAPT trial, is a tool to predict the risk of death or hospitalization for heart failure (HFH) within two years after transcatheter edge-to-edge repair (TEER) of mitral regurgitation using a MitraClip device. We aimed to validate the Score in a Polish population.
methodsPatients with severe mitral regurgitation who underwent TEER with MitraClip at three cardiology centers in Poland between November 2015 and February 2023 were included. Patients were divided into two groups based on the COAPT trail criteria: COAPT eligible and COAPT non-eligible. Clinical data were collected from medical records and the COAPT risk score was calculated for each patient. Outcomes were collected during the two-year follow-up period. The primary endpoint was a composite of all-cause mortality and HFH at two-year follow-up and evaluated in the overall cohort and separately for COAPT-eligible and -non-eligible patients.
resultsA total of 225 patients were included in the study: 134 COAPT eligible (60%) and 91 COAPT non-eligible (40%). Higher COAPT risk score was associated with increased risk of primary endpoint in the overall population and in COAPT-eligible patients. The score demonstrated moderate discrimination (area under curve [AUC] = 0.581) and poor calibration (Hosmer-Lemeshow [HL] p = 0.085) in the overall population, whereas it showed moderate discrimination (AUC = 0.600) and good calibration (HL p = 0.308) in COAPT-eligible patients.
conclusionsIn Polish patients fulfilling COAPT criteria, the COAPT risk score has moderate predictive value for post-procedural outcomes. In COAPT non-eligible patients, novel tools are required to predict outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.